Publications
View AllPatisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials.gov number,...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- US
- Publications
- 4
- Citations
- 13,537
External Links
Identifiers
- ROR
- https://ror.org/04pwc8466